about
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanc...
Read More
2.96
-0.06
(-1.99%)
1.2M
XNAS Volume
XNAS 14 May, 2026 1:33 PM (EDT)
Board Meeting
The latest board meeting for Altimmune Inc took place on 13 May 2026, for the purpose of Altimmune Inc First Quarter Earnings Conference Call for 2026
See details
Not Eligible
Expensive Valuation
Technically Neutral
Altimmune Inc Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..